Quantitation of camptothecin and related compounds.

[1]  T. Oguma,et al.  High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma. , 2001, Biological & pharmaceutical bulletin.

[2]  F. Pinguet,et al.  SENSITIVE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC FLUORESCENCE DETERMINATION OF TOPOTECAN IN HUMAN PLASMA AND PAROTID SALIVA , 2000 .

[3]  H. Zhao,et al.  20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.

[4]  J. Verweij,et al.  Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography , 2000, Anti-cancer drugs.

[5]  Y. Ohshima,et al.  Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[6]  A. Aldaz,et al.  Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[7]  D. Fraier,et al.  Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection. , 2000, Journal of pharmaceutical and biomedical analysis.

[8]  T. Tsai,et al.  Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection. , 2000, Journal of chromatography. A.

[9]  J. Verweij,et al.  Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[10]  T. Thalhammer,et al.  Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver , 2000, Cancer Chemotherapy and Pharmacology.

[11]  S. Clarke,et al.  Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance , 2000, Cancer Chemotherapy and Pharmacology.

[12]  P. Marquet,et al.  Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[13]  T. Tsai,et al.  Determination of unbound 20(S)-camptothecin in rat bile by on-line microdialysis coupled to microbore liquid chromatography with fluorescence detection. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[14]  J. Schellens,et al.  Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[15]  J. Verweij,et al.  Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography. , 1999, Analytical biochemistry.

[16]  A. Kurita,et al.  High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[17]  A. Renard,et al.  Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[18]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[19]  S. Arbuck,et al.  Clinical applications of the camptothecins. , 1998, Biochimica et biophysica acta.

[20]  W. W. ten Bokkel Huinink,et al.  High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.

[21]  S. Clarke,et al.  Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[22]  J. Verweij,et al.  Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[23]  T. Thalhammer,et al.  Biotransformation of topotecan in the isolated perfused rat liver: identification of three novel metabolites. , 1998, Anticancer research.

[24]  J. Robert,et al.  Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. , 1998, The Journal of pharmacology and experimental therapeutics.

[25]  S. Hecht,et al.  Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. , 1998, Biochemistry.

[26]  J. Schellens,et al.  Sensitive Determination of the Carboxylate and Lactone Forms of the Novel Antitumor Drug Irinotecan and Its Active Metabolite in Plasma by HPLC , 1998 .

[27]  N. Ibrahim,et al.  High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[28]  I. Kawamura,et al.  FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome , 1998, Cancer Chemotherapy and Pharmacology.

[29]  D. Craik,et al.  Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. , 1997, Journal of pharmaceutical sciences.

[30]  J. Verweij,et al.  Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[31]  T. Shimazoe,et al.  Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice , 1997, Japanese journal of cancer research : Gann.

[32]  T. Yokokura,et al.  Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography. , 1997, Biological & pharmaceutical bulletin.

[33]  J. Verweij,et al.  Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. , 1997, Journal of Chromatography B: Biomedical Sciences and Applications.

[34]  T. Burke,et al.  Comparison of filter and tunable fluorescence detection for the HPLC simultaneous quantitation of lactone and carboxylate forms of topotecan in plasma , 1997 .

[35]  T. Burke,et al.  Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[36]  J. Verweij,et al.  蛍光検出逆相高速液体クロマトグラフィーによるヒト血しょう中イリノテカン(CPT‐11)とその活性代謝産物SN‐38の定量 , 1997 .

[37]  Toshiaki Takahashi,et al.  Salivary drug monitoring of irinotecan and its active metabolite in cancer patients , 1997, Cancer Chemotherapy and Pharmacology.

[38]  H. Rosing,et al.  Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan , 1997, Cancer Chemotherapy and Pharmacology.

[39]  F. Lokiec,et al.  Irinotecan (CPT-11) metabolites in human bile and urine. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Y. Li,et al.  Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues. , 1996, Journal of chromatography. B, Biomedical applications.

[41]  H. Rosing,et al.  The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. , 1996, Journal of pharmaceutical and biomedical analysis.

[42]  J. Robert,et al.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. , 1996, Cancer research.

[43]  A. Kawai,et al.  Simultaneous determination of a camptothecin derivative, used as an anticancer drug, and its photodegradation products by high-performance liquid chromatography , 1996 .

[44]  K. Uoto,et al.  A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo , 1995, Japanese journal of cancer research : Gann.

[45]  H. Rosing,et al.  High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. , 1995, Journal of chromatography. B, Biomedical applications.

[46]  R. S. St. Claire,et al.  High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. , 1995, Journal of chromatography. B, Biomedical applications.

[47]  K. Uoto,et al.  Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues. , 1994, Journal of medicinal chemistry.

[48]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[49]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[50]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[51]  M. Wani,et al.  Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5'(RS)-1,5-dioxo-5'-ethyl-5'-hydroxy-2'H,5'H,6'H-6'-oxopyrano[3' ,4'- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. , 1987, Journal of medicinal chemistry.

[52]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[53]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .